GlaxoSmithKline, a big pharma company, is discussing pharma deals for the sale of its thrombosis drug brands Arixtra and Fraxiparine, along with a related French factory, to Aspen Pharmacare in a deal that could be worth some $1 billion.
Arixtra and Fraxiparine had worldwide sales of approximately $660 million in 2012, prior to the pharma deals, and revenues are expected to slide further in 2013.
Neither company put a value on the proposed pharma deals but assuming Aspen pays twice this year's anticipated sales, it could be worth around 700 million pounds - after stripping out sales in China, India and Pakistan, which GSK will retain.
About 1,000 GSK employees would transfer to Aspen, as part of the pharma deals if they go through, the majority of whom work at the Notre Dame de Bondeville production site in France.
GSK said the proposed disposal fitted with its strategy of focusing on products with the most growth potential and delivering its new-drug pipeline.
Report: Partnering Deals and Alliances with GlaxoSmithKline
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity